Rebecca L. Hirsh, MD

Call 800-789-7366
Penn Medicine Provider

About me

  • Co-Director, LGBTQ Health
  • Director, Inpatient Oncology Services, Hospital of the University of Pennsylvania
  • Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Medical School: Brown University
  • Residency: Brown University, Rhode Island Hospital
  • Fellowship: NewYork-Presbyterian/Columbia University Medical Center

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Hirsh is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Xiao Wang, Swarn V. Arya, Sonal Patel, Stephen Saw, Mary A. Decena, Rebecca Hirsh, David A. Pegues, Matthew J. Ziegler Antibiotic practice and stewardship in the management of neutropenic fever: a survey of US institutions. , Infection Control & Hospital Epidemiology.: 2024,1-8

Vima M Patel, Brian Chu, Keith W Hamilton, Cassandra Bellamy, Christina Harker, Joshua S Bryer, Bridget Shields, Rebecca L Hirsh, Olajumoke O Fadugba, Robert G Micheletti. Penicillin allergy evaluation in hospitalized patients with hematologic malignancy. , Antimicrobial Stewardship & Healthcare Epidemiology, 3(1): 2023,e92.

Matthew J. Ziegler, Craig Freyer, Daniel Landsburg, David Pegues, Warren Bilker, Rebecca Hirsh, Colleen Kucharczuk, Cheryl Gilmar, Theresa Gorman, Melissa Palmer, Christina Harker, Erin Lightheart, Jennifer H. Han Guideline implementation is effective at reducing proton pump inhibitor use in hematology-oncology units: A multidisciplinary intervention for reducing Clostridioides difficile risk , Infection Control & Hospital Epidemiolog, 40(11):1294-1296. : 2019

Baligh R. Yehia, MD, MPP, MSHP; Daniel Calder, MPH; Judd D. Flesch, MD; Rebecca L. Hirsh, MD; Eve Higginbotham SM, MD; Nancy Tkacs, PhD, RN; Beverley Crawford, DDS; Neil Fishman, MD Advancing LGBT Health at an Academic Medical Center: A Case Study , LGBT Health, 2(4): 2015,362-6

Hirsh RL, DeMichele A. The role of lapatinib in the preoperative therapy of breast cancer , Curr Oncol Rep.: 2012

Hirsh RL, Fox KR Duration of chemotherapy for early stage breast cancer: have we reached the limit? What is the survival impact of amenorrhea? , Curr Treat Options Oncol., 11(3-4): 2010,59-62

Hirsh RL, Fox KR HER2 blockade: is combination therapy better than monotherapy? , Curr Treat Options Oncol., 11(3-4): 2010,63-5

Hirsh RL, Dilip G, Rogers G, Richard S, Neal R Langerhans cell histiocytosis following acute leukemia in an adult. , American Journal of Hematology, 84(10): 2009,693-4

Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG Phase I Trial Evaluating Escalating Doses of Docetaxel and Lenalidomide , J Clin Oncol, 27(15s (suppl)): 2009

Hirsh RL, O’Connor O Current Therapeutic Options in Follicular Lymphoma. , OncologyCases.com: 2008